Sclerodermatous chronic graft-versus-host disease after hematopoietic stem cell transplantation: incidence, clinical characteristics and risk factors.
- Author:
Huan YANG
1
;
Zhi-Tao LI
;
Ren LIN
;
Zhi-Ping FAN
;
Fen HUANG
;
Qian-Li JIANG
;
Hong-Sheng ZHOU
;
Qi-Fa LIU
;
Jing SUN
Author Information
- Publication Type:Journal Article
- MeSH: Graft vs Host Disease; epidemiology; Hematopoietic Stem Cell Transplantation; adverse effects; Humans; Incidence; Risk Factors; Transplantation Conditioning
- From: Journal of Southern Medical University 2016;36(6):807-813
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the incidence and risk factors of sclerodermatous chronic graft-versus-host disease (ScGVHD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
METHODSThe clinical data of 259 patients undergoing allo-HSCT in Nanfang Hospital between January, 2012 and December, 2014 were analyzed.
RESULTSChronic GVHD following allo-HSCT occurred in 134 (51.7%) cases, among whom 22 patients showed sclerodermatous features at a median of 12.5 months (range 4-28 months) after the transplantation. The overall incidence of ScGVHD was 8.49% (22/259) in the recipients and 16.4% (22/134) in those with cGVHD. Univariate analysis showed that the conditioning regimen with total body irradiation (P=0.031), GVHD prophylaxis with MMF (P=0.046), presence of chronic GVHD (P=0.008), and donor lymphocyte infusion (P=0.001) were all closely associated with the occurrence of ScGVHD. Multivariate analysis identified chronic GVHD (RR=3.512, 95%CI: 1.235-9.987, P=0.018) and donor lymphocyte infusion (RR=5.217, 95%CI: 1.698-16.029, P=0.004) as the independent risk factors of ScGVHD.
CONCLUSIONScGVHD following allo-HSCT is not a common complication, and cGVHD and donor lymphocyte infusion are the independent risk factors for ScGVHD.
